Step Therapy and Prior Authorization for Brand-Name Drugs
Defines Cigna's step therapy requirements, prior authorization expectations, and exceptions for certain brand-name medications across multiple therapeutic classes for employer group plans; applies to providers submitting coverage requests under Cigna-administered benefit plans.
Removed the Non-Steroidal Topical therapeutic category and relocated to a new policy, Topical Agents for Atopic Dermatitis Step Therapy Policy (ST005).
Removed the Anti-Parkinsonism Drugs (Carbidopa and Levodopa Products) section effective 4/15/2026 and relocated to a new policy, Parkinson's Disease - Carbidopa-Levodopa (Oral) Step Therapy Policy for Employer Plans (ST006).
Added Zoryve 0.15% cream, as a Step 3 Medication, to the Non-Steroidal Topical section (later relocated to ST005).
Removed Farxiga and Xigduo XR from the Diabetes Care therapeutic category.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.